Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA

International Journal of Neuroscience

Volumn 122, Issue 7, 2012, Pages 358-362

  Coleman, Chandra ^a   Hubble, Jean ^a   Schwab, Joseph ^a   Beffy, Jean Luc ^a   Picaut, Philippe ^a   Morte, Carles ^a  

^a IPSEN   (France)

Author keywords

abobotulinumtoxinA; botulinum toxin; neutralizing antibodies

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY; PLACEBO;

ARTICLE; BLOOD ANALYSIS; CERVICAL DYSTONIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; FOLLOW UP; HUMAN; IMMUNITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RADIOIMMUNOPRECIPITATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; SEVERITY OF ILLNESS INDEX; TORTICOLLIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862201559     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.668725     Document Type: Article

References (22)

1. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Sub-committee of the American Academy of Neurology. Neurology. 2008;70(19):1699-706. (Pubitemid 351644138)
2. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45(9):1743-6.
3. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol. 2006;13 Suppl 1:11-15.
4. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol. 1997;147(1):96-102. (Pubitemid 27402446)
5. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19 Suppl 8:S92-100.
6. Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun. 1997;65(5):1626-30. (Pubitemid 27193578)
7. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-88. (Pubitemid 36418786)
8. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949-51. (Pubitemid 40800714)
9. Frevert J. Xeomin is free from complexing proteins. Toxicon. 2009;54(5):697-701.
10. Panjwani N, O'Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum J. 2008;1(1):153-66.
11. Bakheit AM, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psych. 2004;75(11):1558-61. (Pubitemid 39430607)
12. Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R. Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm. 2009 Apr;116(4):437-41.
13. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783-91. (Pubitemid 41227144)
14. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316-23.
15. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 93-108.
16. Morte C, Pla F, Cedo M, Mirabet M, Peraire C, Obach R, O'Keeffe R, Pickett A. Development of a multi-step approach for the detection of neutralizing antibodies to botulinum toxin type A. Poster session presented at: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; 2008 Jun 12-15; Baveno, Lake Maggiore, Italy.
17. Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, VanDenburgh A, Chapman MA, Brin MF. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indications. Mov Disord. 2010;25(13):2211-18.
18. Naumann M, Yakovleff A, Durif F. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249(1):57-63. (Pubitemid 34119024)
19. Dressler D, Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord. 2002;17(1):170-3. (Pubitemid 36041275)
20. Kranz G, Sycha T, Voller B, Kranz GS, Schnider P, Auff E. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008;70(2):133-6.
21. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol. 1999;246(4):265-74. (Pubitemid 29229352)
22. Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord. 2004;19(3):303-8. (Pubitemid 38961084)